Navigation Links
New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
Date:6/24/2011

IRVING, Texas and ABBOTT PARK, Ill., June 24, 2011 /PRNewswire/ -- New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate (eGFR). The data were also presented today in a Late-Breaking Clinical Trials session at the 2011 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Prague, Czech Republic.

The Phase 2 dose-finding clinical trial, known as the BEAM study, showed that in patients with moderate to severe chronic kidney disease – defined by an eGFR of 20 to 45 mL/min/1.73m2 – and type 2 diabetes, eGFR at 52 weeks was significantly improved with bardoxolone methyl treatment by up to 10.5 mL/min/1.73m2 in patients receiving 75 mg (p<0.001).

"The published data for bardoxolone methyl suggest that it may have potential to delay kidney disease progression in patients with compromised kidney function," said Dr. David Warnock of the University of Alabama at Birmingham, who presented the findings at the ERA-EDTA session and is the senior author of the article.  "Further study to learn more about the clinical benefits of this drug candidate is warranted."

The multi-center, double-blind, placebo-controlled trial enrolled 227 patients who were randomly assigned to receive placebo, 25, 75 or 150 mg of bardoxolone methyl orally, once daily for 52 weeks.

Specifically, the 52-week data showed:

  • At 52 weeks, patients receiving each of the three tested doses of bardoxolone methyl experienced a statistically significant improvement in eGFR, an important measure of kidney function. Increases were 5.8, 10.5 and 9.3 mL/min/1.73m2 for the 25, 75
    '/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... MONMOUTH JUNCTION, N.J. , May 4, 2015 ... critical care immunotherapy company commercializing its CytoSorb® extracorporeal ... patients in multiple countries worldwide, will report Q1 ... Monday, May 11, 2015.  CytoSorbents, ... presentation webcast that will recount both operational and ...
(Date:5/4/2015)... , May 4, 2015 Dynatronics ... manufacturer and marketer of rehabilitation and physical therapy ... definitive agreements to raise approximately $4,000,000 in a ... and certain of its affiliates (together with its ... on the healthcare industry. The financing will provide ...
(Date:5/4/2015)... ROCKVILLE, Md. , May 4, 2015   ... of pathogen-specific therapeutics focused on protecting the microbiome, as ... Shallcross has been appointed Chief Financial Officer, Treasurer ... C. Evan Ballantyne who will be leaving the ... Mr. Shallcross brings to Synthetic Biologics operational, financial and ...
Breaking Medicine Technology:CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 3Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 4Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 2Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 3
... , Inc., a full-service contract research organization (CRO), and ... combat the growing issue of antibiotic resistance, have partnered ... walk to benefit the Cystic Fibrosis (CF) Foundation through ... Aptalis Pharma) are also working together on clinical trials ...
... May 2, 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... March 31, 2012.  For the first quarter of 2012, the ... per share, compared with a net income of $2.9 million, ... 2011. This $3.8 million change in operating results is primarily ...
Cached Medicine Technology:Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure 2Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6
(Date:5/4/2015)... UT (PRWEB) May 04, 2015 Pricing ... (up to $3,000) of one patient receiving care at ... Utah. The procedure must be performed by July 15th, ... to pay in full up front and forego the filing ... becomes more economically burdensome every year, and it devastates more ...
(Date:5/4/2015)... 2015 Unlike some camps, the Nike Middle School ... The goal is to educate first and train second, with a ... that the young runners are building the knowledge base needed to ... the topics covered include Effort Based Training, Running Heroes, Running Vocabulary, ... be? This is not a camp where kids come to ...
(Date:5/4/2015)... 2015 World T.E.A.M. Sports’ best-attended ... in the last decade arrived in this historic Civil ... two days from the Pentagon in Arlington, Virginia. The ... disabled and able-bodied participants work together to successfully complete ... honors the commitment and sacrifices by military veterans in ...
(Date:5/4/2015)... 04, 2015 The Accreditation ... the first-ever congenital heart disease (CHD) standards ... (PCCL) accreditation. Driven by the latest available ... comprehensive review of interventional procedures in pediatric ... , “The ACE CHD Standards for PCCL ...
(Date:5/3/2015)... AvePoint, the established ... devices, today announced it is a Platinum Sponsor ... Asia Privacy Forum, taking place May 5-6, 2015 ... AvePoint will showcase its compliance, risk, and privacy ... Visit AvePoint for New Solutions , Attendees ...
Breaking Medicine News(10 mins):Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 4
... Lemon Grove Care & Rehabilitation Center has responded ... a "AA" citation issued to the 158-bed skilled ... )"We stand by the quality of care we ... the Department,s assessment of the facts surrounding this ...
... women at certain times of year, study finds , , FRIDAY, ... people,s attempts to get regular exercise, suggests a U.S. study ... and less in the winter. , The study involved ... 18 months. Based on pedometer readings, the women,s step counts ...
... College of Optometry students receive a Jenzabar Foundation grant to impact ... ... (PRWEB) February 13, 2009 -- Even in this uncertain economy, ... and wallets to volunteer for domestic and global humanitarian missions through ...
... Treat Diseases, Inc. (HTDS) ( www.htdsmedical.com ) has entered ... company that has developed a radically new product which ... the FDA approval (or authority equivalent to the specific ... FDA approved. , HTDS Andrea Zecevic-Rubio, Chief Project Scientist, ...
... 13 American Network, Inc., announced today that it ... for the Deaf and Hard of Hearing communities. ... a great success as it forays into TRS with ... and Hard of Hearing.PhoneCaption,s service uses innovative, patent-pending technology ...
... Feb. 13 Six Miami-Dade County residents have been ... fraud scheme operated out of Midway Medical, a Miami ... Acting Assistant Attorney General Rita M. Glavin of the ... the Southern District of Florida announced.Carmen Lourdes del Cueto, ...
Cached Medicine News:Health News:Lemon Grove Care & Rehabilitation Center Responds to Health Department Announcement 2Health News:Winter's Cold, Summer's Heat Take a Toll 2Health News:Cash-strapped Optometry Students Give Back in a Big Way 2Health News:Cash-strapped Optometry Students Give Back in a Big Way 3Health News:Cash-strapped Optometry Students Give Back in a Big Way 4Health News:Hard To Treat Diseases (HTDS) Negotiating to Merge with a UK Health Care Company 2Health News:PhoneCaption Provides Free Captioning Services for Deaf and Hard of Hearing 2Health News:Three Miami Physicians and Three Medical Workers Charged With $10 Million Medicare Fraud Scheme 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: